Structural requirements of glycosaminoglycans for their interaction with HIV-1 envelope glycoprotein gp120

Archives of Virology

Volumn 159, Issue 3, 2014, Pages 555-560

  Matos, Pedro M ^a   Andreu, David ^b   Santos, Nuno C ^a   Gutiérrez Gallego, Ricardo ^b,c  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Glycosaminoglycans; gp120; Heparan sulfate proteoglycans; HIV 1; Surface plasmon resonance; Viral attachment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

GLYCOPROTEIN GP 120; GLYCOSAMINOGLYCAN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CHEMISTRY; METABOLISM; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

GLYCOSAMINOGLYCANS; HIV ENVELOPE PROTEIN GP120; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

EID: 84896720324     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-013-1831-3     Document Type: Article

References (22)

1. Klasse PJ (2012) The molecular basis of HIV entry. Cell Microbiol 14: 1183-1192.
2. Melikyan GB (2011) Membrane fusion mediated by human immunodeficiency virus envelope glycoprotein. Curr Top Membr 68: 81-106.
3. Ugolini S, Mondor I, Sattentau QJ (1999) HIV-1 attachment: another look. Trends Microbiol 7: 144-149.
4. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777.
5. Esko JD, Kimata K, Lindahl U (2009) Proteoglycans and Sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of Glycobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
6. Mbemba E, Czyrski JA, Gattegno L (1992) The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein. Biochim Biophys Acta 1180: 123-129.
7. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA (1995) Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 69: 2233-2239.
8. Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H (2005) Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280: 21353-21357.
9. Crublet E, Andrieu JP, Vives RR, Lortat-Jacob H (2008) The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J Biol Chem 283: 15193-15200.
10. de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA (2005) A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem 280: 39493-39504.
11. Mondor I, Ugolini S, Sattentau QJ (1998) Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 72: 3623-3634.
12. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD (2002) Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 76: 6332-6343.
13. Bobardt MD, Saphire AC, Hung HC, Yu X, van der Schueren B, Zhang Z, David G, Gallay PA (2003) Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18: 27-39.
14. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA (2001) Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 75: 9187-9200.
15. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB, Gallay P (2007) Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci USA 104: 19464-19469.
16. Gallay P (2004) Syndecans and HIV-1 pathogenesis. Microbes Infect 6: 617-622.
17. Rider CC, Coombe DR, Harrop HA, Hounsell EF, Bauer C, Feeney J, Mulloy B, Mahmood N, Hay A, Parish CR (1994) Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33: 6974-6980.
18. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446: 1030-1037.
19. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269: 18881-18890.
20. Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA (2010) Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother 54: 2753-2766.
21. Baleux F, Loureiro-Morais L, Hersant Y, Clayette P, Arenzana-Seisdedos F, Bonnaffe D, Lortat-Jacob H (2009) A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. Nat Chem Biol 5: 743-748.
22. Connell BJ, Baleux F, Coic YM, Clayette P, Bonnaffe D, Lortat-Jacob H (2012) A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti- HIV-1 activity independently of coreceptor usage. Chem Biol 19: 131-139.